Chronic Lymphocytic Leukemia Clinical Trials in Columbus, Ohio

17 studies are recruiting for chronic lymphocytic leukemia in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

   This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymph…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   632 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04269902 on ClinicalTrials.gov

2. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

   This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

   Stage

   Not phased

   Ages

   40 to 75

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   745 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05334069 on ClinicalTrials.gov

3. Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

   This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhi…

   Stage

   Phase 3

   Ages

   65 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   210 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT07321652 on ClinicalTrials.gov

4. Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

   This phase II trial tests the effect of venetoclax in combination with standard of care (SOC) zanubrutinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may st…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Kerry Rogers

   See if you can join NCT07734038 on ClinicalTrials.gov

5. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

   This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

   Stage

   Phase 1

   Ages

   13 to 90

   Site

   The Ohio State University Wexner Medical Center, Columbus, Ohio

   Locations

   11 in total

   Run by

   Vironexis Biotherapeutics Inc.

   See if you can join NCT06533579 on ClinicalTrials.gov

6. A Long-term Extension Study of PCI-32765 (Ibrutinib)

   The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively rece…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   The Ohio State University- James Cancer Hospital, Columbus, Ohio

   Locations

   175 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT01804686 on ClinicalTrials.gov

7. A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

   The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   11 in total

   Run by

   Curis, Inc.

   See if you can join NCT07271667 on ClinicalTrials.gov

8. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

   This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

   Stage

   Phase 1

   Ages

   13 and older

   Site

   The Ohio State University, Columbus, Ohio

   Locations

   8 in total

   Run by

   Newave Pharmaceutical Inc

   See if you can join NCT04771572 on ClinicalTrials.gov

9. A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

   The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studie…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   38 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06876649 on ClinicalTrials.gov

10. A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

    Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned stu…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Locations

    36 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06876662 on ClinicalTrials.gov

11. Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

    This phase II trial tests whether acalabrutinib in combination with venetoclax or obinutuzumab works to shrink tumors in patients with treatment-naive chronic lymphocytic leukemia . Acalabrutinib is also an inhibitor that works in the body to block the activation of certain cells that lead to the g…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Ohio State University Comprehensive Cancer Center

    See if you can join NCT05336812 on ClinicalTrials.gov

12. Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

    This phase II trial tests how well pirtobrutinib (LOXO-305) and venetoclax works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that remains despite treatment (resistant) with covalent bruton tyrosine kinase inhibitors (BTKi). Pirtobrutinib is in a …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Kerry Rogers

    See if you can join NCT06466122 on ClinicalTrials.gov

13. Study of SGR-1505 in Mature B-Cell Neoplasms

    The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Ohio State University - The James Cancer Hospital, Columbus, Ohio

    Locations

    36 in total

    Run by

    Schrödinger, Inc.

    See if you can join NCT05544019 on ClinicalTrials.gov

14. Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

    This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leukemia. At present chronic lymphocytic leukemia patients are poorly protected by anti-pneumococcal vac…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Seema Bhat

    See if you can join NCT05417165 on ClinicalTrials.gov

15. Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

    This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in thi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Locations

    5 in total

    Run by

    Christine Ryan

    See if you can join NCT06043674 on ClinicalTrials.gov

16. Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

    This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six cycles (21-day cycles) of therapy. …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Ohio state University, Columbus, Ohio

    Locations

    4 in total

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT04679012 on ClinicalTrials.gov

17. Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

    This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Locations

    45 in total

    Run by

    Kartos Therapeutics, Inc.

    See if you can join NCT04502394 on ClinicalTrials.gov